{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'functions). A medically significant AE that may jeopardize the participant and may require medical or surgical', 'intervention to prevent one of the outcomes listed in this definition', 'Events NOT considered to be Serious are:', 'Hospitalization for treatment, which was elective or pre-planned, for a pre-existing condition that did not', 'worsen', 'Treatment on an emergency, outpatient basis for an event NOT fulfilling any of the definitions of serious given', 'above and NOT resulting in hospital admission', 'An event that, had it occurred in a more serious form, might have caused death', 'A sign, symptom, or event that is noticeable but easily tolerated.', 'An event does not significantly influence performance or prevent the participant from carrying on with their', 'usuall life activities.', '9.3.3 CLASSIFICATION OF AN ADVERSE EVENT', '9.3.3.1 SEVERITY OF EVENT', 'The severity of adverse changes in physical signs or symptoms will be classified as follows:', 'Grade 1 (Mild): Asymptomatic or mild symptoms; clinical or diagnostic observation only;', 'intervention not indicated.', 'Grade 2 (Moderate): Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental', 'ADL (Activities of Daily Living).', 'Grade 3 (Serious): Medically significant but not immediately life-threatening; hospitalization or prolongation of', 'hospitalization indicated; disabling; limiting self-care ADL.', 'Grade 4 (Life-threatening): Consequences; urgent intervention indicated.', 'Grade 5 (Death): Event is a direct cause of death.', 'A sign, symptom, or event that causes serious discomfort to the participant and significantly affects clinical status or the', 'ability to perform normal daily life activities. Treatment intervention is warranted.', '9.3.3.2 RELATIONSHIP TO STUDY INTERVENTION', 'An event is related to the research if, in the opinion of the UAB/UM investigator, it was more likely than not to be the', 'result of the interventions and interactions used in the research (i.e., there is a reasonable possibility that the event may', 'have been caused by participation in the research).', \"The determination of the likelihood that the study drug caused the AE will be provided by the site PI. The site PI's\", 'signature and date on the source document and eCRF that supports the causality noted on the AE form, ensures that a', 'medically qualified assessment of causality was done. The assessment of relationship will be reported by the site Pls', 'according to his/her best clinical judgment the following scale of criteria may be used as a guidance (not all criteria will', 'be present in order to be indicative of a drug relationship).', '27']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Definitely Related to the Research:', 'There is evidence of exposure to the study drug', 'The temporal sequence of the AE onset relative to administration of the study drug is reasonable', 'The AE is explained by the study drug', 'Probably Related to the Research:', 'There is evidence of exposure to the study drug', 'The temporal sequence of the AE onset relative to administration of the study drug is reasonable', 'The AE is more likely explained by the study drug than by another cause', 'Possibly Related to the Research:', 'There is evidence of exposure to study drug', 'The temporal sequence of the AE onset relative to administration of the study drug is reasonable', 'The AE could have been due to another equally likely cause', 'Unlikely Related to the Research:', 'There is evidence of exposure to the study drug', 'There is another more likely cause of the AE', 'There is no temporal relationship to study drug', 'Unrelated to the Study Drug:', 'There is no evidence of exposure to the study drug', 'There is another more likely cause of the AE', 'There is no temporal relationship to study drug', 'For all presumed Serious/SAE a study safety event report will completed and submitted to the Data Safety Monitoring', 'Board (DSMB) (see MOOP Section 2.m) and IRB after validation of event. Monitoring of these outcome events will begin', 'as soon as a study participant is enrolled and will continue until the end of the observation period. The DSMB will', 'provide independent oversight and act in an advisory capacity to monitor research participant safety and data quality', 'and to alert the NIAMS to potential issues.', '9.3.3.3 EXPECTEDNESS', 'Expected potential AEs Associated with MMF (see also section 2.3.1)', 'Gastrointestinal: Nausea and vomiting (12%), diarrhea', 'Hematologic & oncologic: Leukopenia (renal transplant: > 50%; RA: 28%), neoplasia (renal transplant: 3%', '(other than lymphoma), 0.5% (lymphoma)), thrombocytopenia', 'Hepatic: Hepatotoxicity, increased serum alkaline phosphatase, increased serum bilirubin, increased serum', 'transaminases', 'Infection: Increased susceptibility to infection (renal transplant 20%; RA <1%; includes bacterial, fungal,', 'protozoal, viral, opportunistic, and reactivation of latent infections)', 'Expected potential AEs associated with Pegloticase (see also section 2.3.1)', 'During pre-marketing controlled clinical trials, infusion reactions were reported in 26% of patients treated with', 'pegloticase 8 mg every 2 weeks. During pre-marketing controlled clinical trials, anaphylaxis was reported with a', 'frequency of 6.5% for patients treated with pegloticase. For the purposes of this study, these events shall be defined as', 'follows:', 'IR (see Section 8.3.8.1) not attributable to another cause that occurs during or within 2 hours after the', '28']\n\n###\n\n", "completion": "END"}